ReviewChemical science2026
Virus-like particles based on plant viruses and bacteriophages: emerging strategies for the delivery of nucleic acid therapeutics.
Review in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-acting RNAi therapeutics in hypertension: limitations of single-target AGT silencing and rational multi-target synergistic strategies.Frontiers in pharmacology · 2026Review
- Engineering strategies and decision frameworks for virus-like particle-based vaccines against infectious diseases.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nucleic acids have emerged as a robust modality for the treatment of various diseases that are considered undruggable in the context of small-molecule therapeutics. However, their clinical translation is hindered by the lack of safe and effective delivery across extracellular and intracellular barriers. Mammalian viral vectors and synthetic non-viral carriers have long dominated the delivery landscape, but these raise concerns about safety and immunogenicity, driving the search for alternative strategies. Recently, non-mammalian viral vectors (based on plant viruses or bacteriophages) and virus-like particles (VLPs) derived from them have gained attention as bioinspired platforms for nucleic acid drug delivery. Their well-defined architecture, scalable production, and ability to encapsulate or display drug cargoes offer versatility for drug delivery. This review highlights recent progress in the engineering of plant viruses and bacteriophages for nucleic acid delivery, emphasizing their potential as non-infectious viral scaffolds for next-generation therapeutic platforms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.